{"url_path":"/sec/obio/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1814114/0001104659-26-059382-index.html","accession_number":"0001104659-26-059382","cik":"0001814114","ticker":"OBIO","issuer_name":"Orchestra BioMed Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1814114/0001104659-26-059382-index.html","primary_entity_key":"0001814114","primary_entity_name":"Orchestra BioMed Holdings, Inc."},"word_count":67,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nRule 10b5-1 Trading Arrangements\n\n​\n\nDuring the three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(c) of Regulation S-K.\n\n​\n\n​\n\n41\n\n[Table of Contents](#TOC)"}